“Effect of Hormone Resistance Type on First-Line Treatment Selection in ER+ HER2-Negative Metastatic Breast Cancer”. Voprosy Onkologii, vol. 72, no. 3, July 2026, p. OF-2675, https://doi.org/10.37469/0507-3758-2026-72-3-OF-2675.